Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 12 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The Company incorporated into operating profit and ordinary profit the upfront fee associated with entering into the license agreement for EB05 with Edesa Biotech, Inc., and reflected in net income the loss on transfer of business related to the transfer of the generic drugs business, which was recognized as an extraordinary loss in the interim consolidated accounting period.
Loss on transfer of business related to the transfer of the generic drugs business (amount: Not disclosed)
| Item | Details |
|---|---|
| Net Sales | ¥121,800 million → ¥121,800 million |
| Operating profit | ¥2,000 million → ¥-4,900 million |
| Ordinary income | ¥2,300 million → ¥-4,600 million |
| Profit attributable to owners of the parent | ¥1,500 million → ¥-5,100 million |
| Net income per share | 26.11 Yen and sen → -88.74 Yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 12 May 2026 |
| Previous-period results | Consolidated: revenue, ¥126,257 million; operating profit, ¥3,567 million; ordinary profit, ¥4,031 million; net income attributable to owners of the parent, ¥3,448 million; net income per share, ¥60.03. Standalone: revenue, ¥110,934 million; operating profit, ¥4,285 million; ordinary profit, ¥5,048 million; net income, ¥4,183 million; net income per share, ¥72.82. |
| Reason for the revision | The Company incorporated into operating profit and ordinary profit the upfront fee associated with entering into the license agreement for EB05 with Edesa Biotech, Inc., and reflected in net income the loss on transfer of business related to the transfer of the generic drugs business, which was recognized as an extraordinary loss in the interim consolidated accounting period. |
| Details and amount of extraordinary loss | Loss on transfer of business related to the transfer of the generic drugs business (amount: Not disclosed) |
| Consolidated / non-consolidated | Consolidated/non-consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the interim period, revenue from Rasivick, Mucodyne and other products was below forecast, while operating profit and ordinary profit exceeded forecast because selling, general and administrative expenses were below budget. Interim net income was below forecast because a loss on transfer of business related to the transfer of the generic drugs business was recognized as an extraordinary loss. The full-year forecasts were revised to reflect the upfront fee associated with the license agreement for EB05, the upfront fee related to products under discussion, and the loss on transfer of business.